ArticleCancer research2010
The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Target neutrophil heterogeneity and plasticity in cancer.Journal of hematology & oncology · 2025Review
- Neutrophils in the premetastatic niche: key functions and therapeutic directions.Molecular cancer · 2024Review
- Effect of ischemia-reperfusion injury on elafin levels in rat liver.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2024Article
- Article
- Tumor-associated neutrophils in pancreatic cancer progression and metastasis.American journal of cancer research · 2023Review
- Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer.Oncogene · 2022Article
- Combination of levofloxacin and cisplatin enhances anticancer efficacy via co-regulation of eight cancer-associated genes.Discover oncology · 2022Article
- Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression.Journal for immunotherapy of cancer · 2021Article
- Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Article
- Neutrophils in the Tumor Microenvironment.Advances in experimental medicine and biology · 2020Review
- Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic.Frontiers in immunology · 2020Review
- The Clinical Significance of DNA Damage Repair Signatures in Clear Cell Renal Cell Carcinoma.Frontiers in genetics · 2020Article
- Tumour-associated neutrophils in patients with cancer.Nature reviews. Clinical oncology · 2019Review
- Tumor-Associated Neutrophils in Cancer: Going Pro.Cancers · 2019Review
- Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo.Scientific reports · 2018Article
- WAP four-disulfide core domain protein 2 promotes metastasis of human ovarian cancer by regulation of metastasis-associated genes.Journal of ovarian research · 2017Article
- The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.Oncogene · 2015Article
- Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors.Oncogene · 2015Article
- Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cells.Cell cycle (Georgetown, Tex.) · 2014Article
- Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.Breast cancer research : BCR · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Elafin, an endogenous inhibitor of neutrophil elastase, is expressed in human mammary epithelial cells but is transcriptionally downregulated in breast cancer cells. We hypothesized that elafin may exert a tumor-suppressive activity in the context of breast cancer. In this study, we show that the retinoblastoma (Rb) pathway governs the antitumor properties of elafin. In breast cancer cells with functional Rb, the expression of elafin triggered Rb-dependent cell cycle arrest. Elafin also exhibited suppressive activity in breast cancer cell lines lacking Rb, but this was associated with an induction of caspase-3-dependent, p53-independent apoptotic cell death. Normal mammary epithelial cells were not affected by elafin. Collectively, these results argue that elafin mediates tumor-suppressive effects that are cytostatic or cytotoxic depending on the Rb status. Our findings suggest that elafin could be engineered as a therapeutic modality to treat breast cancer without toxicity to normal proliferating cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.